Beneficient Q2 GAAP EPS of -$1.49, revenue of -$25.29M

Beneficient (BENF) reported Q2 GAAP EPS of -$1.49 and revenue of -$25.29M, down 816.3% year-over-year. Operating expenses decreased 6.9% to $14.06M. The company closed a $7.4M deal and held $7.48M in cash and $201.05M in investments.

Original reporting
Published Nov 16, 2026, 11:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 11:12 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Beneficient Q2 GAAP EPS of -$1.49, revenue of -$25.29M — source image
Decision brief

The 30-second read

$BENFBearishMed
01

Why it matters

The combination of large revenue contraction, negative GAAP EPS, and cash on hand is likely to drive near-term sentiment and valuation recalibration, while the disclosed capital deal and investment fair values may temper the reaction.

02

Market read

This is a company-specific earnings print with balance-sheet and financing details that can change trading expectations immediately.

03

What to watch

The article does not provide guidance, segment detail, or valuation/mark-to-market drivers behind the fair-value investments, which could materially change how the losses are interpreted.

Relevance 8/10Novelty 8/10Timing: after-hours/overnight following the Q2 earnings release

Background

The piece summarizes Beneficient’s Q2 results from a company press release, including GAAP and non-GAAP operating expense trends and balance-sheet items.

Company-level read

Ticker impact

$BENFBearishMedium confidence
Context

Beneficient reports Q2 GAAP EPS of -$1.49 and revenue of -$25.29M, plus a $7.4M GP primary capital deal and $7.48M cash.

Expected impact

Likely downside bias as investors price in continued operating losses and revenue contraction, with limited support from the new capital deal.

Evidence & confidence

The article discloses the quarter’s GAAP EPS and revenue figures and cash position, which are direct fundamentals for near-term valuation; the capital deal is supportive but smaller than the revenue decline magnitude.

Market effects

Adds datapoint on performance and funding dynamics for niche financial services/GP primary capital structures.

No clear regional spillover indicated by the article.

No direct global macro or cross-border linkage described.

Counterpoint

Investors may focus on the $201.05M fair-value investment portfolio and the $7.4M GP primary capital deal as evidence of ongoing capital access despite GAAP losses.

Key entities

  • Beneficient

    Reports Q2 GAAP EPS -$1.49, revenue -$25.29M, operating expense reductions, a $7.4M GP primary capital deal, $7.48M cash, and $201.05M fair-value investments.

Related articles

$BENFMed

BENEFICIENT REPORTS SECOND QUARTER FISCAL 2027 RESULTS

Beneficient (BENF) filed an SEC Form 8-K — Results of Operations and Financial Condition. For Immediate Release BENEFICIENT REPORTS SECOND QUARTER FISCAL 2027 RESULTS Company Advances Strategic Initiatives, Expands Transaction Activity, Reduces Operating Costs and Improves Liquidity Dallas, TX. – November 16, 2026 (GlobeNewswire) – Beneficient (NASDAQ: BENF) (“Ben” or